Skip to main content
Premium Trial:

Request an Annual Quote

Added to the Label

The US Food and Drug Administration has updated the label of the Johnson & Johnson SARS-CoV-2 vaccine to include a warning that it is linked to an increased risk of a rare neurological condition, the Verge reports.

NPR adds that about 12 million doses of the J&J vaccine have been administered in the US and there have been 100 reports of people developing Guillain-Barré syndrome. The condition, which the Verge notes has been linked to other vaccines in the past, is marked by numbness in the extremities that can lead to paralysis, though most people recover. According to the Centers for Disease Control and Prevention, most cases of Guillain-Barré following inoculation involved men over the age of 50, NPR adds.

"It appears that this is an extremely rare occurrence and one in which the risk-benefit ratio still strongly favors the vaccine," Amesh Adalja from the Johns Hopkins University Center for Health Security tells the Huffington Post.

The vaccine factsheet now notes the increased, but still low risk of developing the condition.

The Verge notes this is the second health risk linked to the J&J vaccine, as it is also associated with an increased risk of a rare blood clotting disorder.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.